Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction ( VICTORIA ) trial

Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.AIMSWhether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.We studied 488...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of heart failure Vol. 25; no. 10; pp. 1822 - 1830
Main Authors Yogasundaram, Haran, Zheng, Yinggan, Ly, Eric, Ezekowitz, Justin, Ponikowski, Piotr, Lam, Carolyn S.P., O'Connor, Christopher, Blaustein, Robert O., Roessig, Lothar, Temple, Tracy, Westerhout, Cynthia M., Armstrong, Paul W., Sandhu, Roopinder K.
Format Journal Article
LanguageEnglish
Published 01.10.2023
Online AccessGet full text

Cover

Loading…
Abstract Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.AIMSWhether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.We studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all-cause deaths. Median age was 68 years (interquartile range [IQR] 60-76), 24% were women, median ejection fraction was 30% (IQR 23-35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19-28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all-cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all-cause death (HR 1.44). The only sex-based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction  = 0.024) and all-cause death (men: HR 0.99; women: HR 1.57; pinteraction  = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87-1.79; female: HR 2.50, 95% CI 1.23-5.06; pinteraction  = 0.141).METHODS AND RESULTSWe studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all-cause deaths. Median age was 68 years (interquartile range [IQR] 60-76), 24% were women, median ejection fraction was 30% (IQR 23-35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19-28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all-cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all-cause death (HR 1.44). The only sex-based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction  = 0.024) and all-cause death (men: HR 0.99; women: HR 1.57; pinteraction  = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87-1.79; female: HR 2.50, 95% CI 1.23-5.06; pinteraction  = 0.141).Routine ECG measurements provide additional prognostication of mortality in high-risk HFrEF patients, particularly in women with contiguous pathologic Q waves.CONCLUSIONRoutine ECG measurements provide additional prognostication of mortality in high-risk HFrEF patients, particularly in women with contiguous pathologic Q waves.
AbstractList Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.AIMSWhether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.We studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all-cause deaths. Median age was 68 years (interquartile range [IQR] 60-76), 24% were women, median ejection fraction was 30% (IQR 23-35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19-28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all-cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all-cause death (HR 1.44). The only sex-based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction  = 0.024) and all-cause death (men: HR 0.99; women: HR 1.57; pinteraction  = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87-1.79; female: HR 2.50, 95% CI 1.23-5.06; pinteraction  = 0.141).METHODS AND RESULTSWe studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all-cause deaths. Median age was 68 years (interquartile range [IQR] 60-76), 24% were women, median ejection fraction was 30% (IQR 23-35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19-28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all-cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all-cause death (HR 1.44). The only sex-based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction  = 0.024) and all-cause death (men: HR 0.99; women: HR 1.57; pinteraction  = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87-1.79; female: HR 2.50, 95% CI 1.23-5.06; pinteraction  = 0.141).Routine ECG measurements provide additional prognostication of mortality in high-risk HFrEF patients, particularly in women with contiguous pathologic Q waves.CONCLUSIONRoutine ECG measurements provide additional prognostication of mortality in high-risk HFrEF patients, particularly in women with contiguous pathologic Q waves.
Author Westerhout, Cynthia M.
Armstrong, Paul W.
O'Connor, Christopher
Lam, Carolyn S.P.
Ly, Eric
Ponikowski, Piotr
Roessig, Lothar
Blaustein, Robert O.
Temple, Tracy
Yogasundaram, Haran
Zheng, Yinggan
Sandhu, Roopinder K.
Ezekowitz, Justin
Author_xml – sequence: 1
  givenname: Haran
  surname: Yogasundaram
  fullname: Yogasundaram, Haran
  organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada
– sequence: 2
  givenname: Yinggan
  surname: Zheng
  fullname: Zheng, Yinggan
  organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada
– sequence: 3
  givenname: Eric
  surname: Ly
  fullname: Ly, Eric
  organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada
– sequence: 4
  givenname: Justin
  surname: Ezekowitz
  fullname: Ezekowitz, Justin
  organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada
– sequence: 5
  givenname: Piotr
  surname: Ponikowski
  fullname: Ponikowski, Piotr
  organization: Institute of Heart Diseases, Wroclaw Medical University Wroclaw Poland
– sequence: 6
  givenname: Carolyn S.P.
  surname: Lam
  fullname: Lam, Carolyn S.P.
  organization: National Heart Centre Singapore, Singapore & Duke‐National University of Singapore Singapore Singapore
– sequence: 7
  givenname: Christopher
  surname: O'Connor
  fullname: O'Connor, Christopher
  organization: Inova Heart and Vascular Institute Falls Church VA USA
– sequence: 8
  givenname: Robert O.
  surname: Blaustein
  fullname: Blaustein, Robert O.
  organization: Merck & Co., Inc. Whippany NJ USA
– sequence: 9
  givenname: Lothar
  surname: Roessig
  fullname: Roessig, Lothar
  organization: Bayer AG Wuppertal Germany
– sequence: 10
  givenname: Tracy
  surname: Temple
  fullname: Temple, Tracy
  organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada
– sequence: 11
  givenname: Cynthia M.
  surname: Westerhout
  fullname: Westerhout, Cynthia M.
  organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada
– sequence: 12
  givenname: Paul W.
  surname: Armstrong
  fullname: Armstrong, Paul W.
  organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada
– sequence: 13
  givenname: Roopinder K.
  surname: Sandhu
  fullname: Sandhu, Roopinder K.
  organization: Canadian VIGOUR Centre University of Alberta Edmonton AB Canada
BookMark eNptkcFO3DAQhqOKSgXaQ99gjnAI2I6TeHtDKxYiISEtW66R40w23iZxajtC3HiEPmNfoS9QZ8Op6skjzzefPP7PopPBDBhFXym5ooSwazy0zVVCGP0QnVKRr2IiOD8JdSJEvBKcfYrOnDsQQvOAn0Z_tthJr83gWj1Chf4FcYBKOuz0gIAdKm-NkrbWZm_l2GoFPUo3Wexx8A7kUIOZvDI9OtADjMF2bLxo30Kr9-3vt19Wux_QorQeGqm7MPwNisGFZgAba3rwLcIz2mKt95PcwV1nKtnBk5_q19n6NFWH8JJ36_3RtFlMy9UW60lhDbczFtaBjZVLcQHPxXr3uC1u4BK81bL7HH1sZOfwy_t5Hn3f3O7W9_HD412xvnmIFcuYj5MUOauruslSySue0zRjyBshmlyIPOUEeZXzNKWSKExXFSKvBa_YKnw7FUmWnEcXi3e05ueEzpe9dgq7Tg5oJlcykRFOUsZoQK8XVFnjnMWmVNofc_E2rFlSUs7xlnO85RxvmLj8Z2K0upf29T_sXwqerj8
CitedBy_id crossref_primary_10_1002_ejhf_3070
crossref_primary_10_3389_fphar_2024_1359939
crossref_primary_10_1002_ejhf_3392
Cites_doi 10.1016/j.jchf.2017.08.013
10.1136/hrt.2006.102319
10.1002/ejhf.561
10.1093/eurheartj/ehs337
10.1016/j.jacc.2018.08.1038
10.1161/01.hyp.25.2.242
10.1002/ejhf.2333
10.1161/01.cir.95.12.2660
10.1016/j.jacc.2008.12.015
10.1016/j.hrthm.2015.01.023
10.1056/NEJMoa1609758
10.1093/eurheartj/ehaa177
10.1016/j.jacc.2018.11.049
10.1007/s11739‐012‐0862‐1
10.1016/j.hrthm.2011.08.031
10.1016/j.jacc.2007.01.024
10.1016/j.amjmed.2015.11.035
10.1002/ejhf.2468
10.1161/CIRCULATIONAHA.105.584102
10.1016/j.ijcard.2009.08.005
10.1016/j.amjcard.2007.07.077
10.1253/circrep.CR‐19‐0025
10.1161/CIR.0b013e31829e8807
10.1161/CIRCHEARTFAILURE.123.010599
10.1093/eurheartj/ehi555
10.1161/CIRCULATIONAHA.108.191095
10.1016/j.jacc.2008.12.014
10.1001/jama.299.22.2656
10.1016/j.cardfail.2013.11.005
10.1007/s00392‐017‐1162‐6
10.1093/eurheartj/ehl259
10.1056/NEJMoa1401426
10.1016/j.ahj.2012.10.009
10.1111/j.1542‐474X.1997.tb00325.x
10.1056/NEJMoa1915928
10.1016/s0735‐1097(00)01102‐5
10.1093/europace/euw065
10.1016/j.amjcard.2010.11.010
10.1016/j.cardfail.2021.05.016
10.1016/j.cjca.2017.08.022
10.1093/eurheartj/ehz835
10.1002/ejhf.2285
10.1093/eurjhf/hfq002
10.1111/j.1542‐474X.2009.00345.x
ContentType Journal Article
Copyright 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Copyright_xml – notice: 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
CorporateAuthor for the VICTORIA Study Group
CorporateAuthor_xml – name: for the VICTORIA Study Group
DBID AAYXX
CITATION
7X8
DOI 10.1002/ejhf.3021
DatabaseName CrossRef
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-0844
EndPage 1830
ExternalDocumentID 10_1002_ejhf_3021
GroupedDBID ---
--K
.I3
0R~
1B1
1OC
1~5
29G
2WC
33P
4G.
53G
5GY
5VS
6PF
7-5
70D
AAESR
AAFWJ
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAPNW
AASGY
AAWTL
AAXRX
AAYCA
AAYXX
AAZKR
ABCUV
ABDBF
ABJNI
ABKDP
ABLJU
ABQWH
ABXGK
ABZBJ
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACRPL
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADEYI
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AENEX
AEQDE
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFWVQ
AGHNM
AGKEF
AGQPQ
AGYGG
AHBTC
AIACR
AIJHB
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
AVWKF
AZFZN
AZVAB
BDRZF
BFHJK
BHBCM
BMXJE
BRXPI
C45
CITATION
CKLRP
CS3
CZ4
DCZOG
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBD
EBS
EJD
EMOBN
ESX
F5P
FEDTE
FUBAC
G-S
GODZA
H13
HGLYW
HVGLF
HZ~
IHE
KBYEO
LATKE
LEEKS
LITHE
LOXES
LUTES
LYRES
M41
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N9A
NQ-
O0~
O66
O9-
OK1
OVD
O~Y
P2P
P2W
Q1.
RD5
RIG
ROL
RPZ
RXO
SDG
SEL
SEW
SUPJJ
SV3
TEORI
TUS
UHS
V9Y
W8F
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WVDHM
WXSBR
X7H
~91
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
ID FETCH-LOGICAL-c262t-35e42dbdf65a4b471562e4f88f7887540e4b74551a0ce59bee4d84b2987918363
ISSN 1388-9842
1879-0844
IngestDate Fri Jul 11 08:12:09 EDT 2025
Tue Jul 01 01:54:30 EDT 2025
Thu Apr 24 23:08:27 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c262t-35e42dbdf65a4b471562e4f88f7887540e4b74551a0ce59bee4d84b2987918363
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PQID 2860405221
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2860405221
crossref_citationtrail_10_1002_ejhf_3021
crossref_primary_10_1002_ejhf_3021
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-10-00
20231001
PublicationDateYYYYMMDD 2023-10-01
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-00
PublicationDecade 2020
PublicationTitle European journal of heart failure
PublicationYear 2023
References e_1_2_6_32_1
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_30_1
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_39_1
e_1_2_6_15_1
e_1_2_6_38_1
e_1_2_6_16_1
e_1_2_6_37_1
e_1_2_6_42_1
e_1_2_6_43_1
e_1_2_6_21_1
e_1_2_6_20_1
e_1_2_6_41_1
e_1_2_6_40_1
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_24_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_22_1
e_1_2_6_29_1
e_1_2_6_44_1
e_1_2_6_28_1
e_1_2_6_45_1
e_1_2_6_27_1
e_1_2_6_26_1
References_xml – ident: e_1_2_6_20_1
  doi: 10.1016/j.jchf.2017.08.013
– ident: e_1_2_6_6_1
  doi: 10.1136/hrt.2006.102319
– ident: e_1_2_6_8_1
  doi: 10.1002/ejhf.561
– ident: e_1_2_6_28_1
  doi: 10.1093/eurheartj/ehs337
– ident: e_1_2_6_25_1
  doi: 10.1016/j.jacc.2018.08.1038
– ident: e_1_2_6_44_1
  doi: 10.1161/01.hyp.25.2.242
– ident: e_1_2_6_5_1
  doi: 10.1002/ejhf.2333
– ident: e_1_2_6_15_1
  doi: 10.1161/01.cir.95.12.2660
– ident: e_1_2_6_24_1
  doi: 10.1016/j.jacc.2008.12.015
– ident: e_1_2_6_39_1
  doi: 10.1016/j.hrthm.2015.01.023
– ident: e_1_2_6_13_1
  doi: 10.1056/NEJMoa1609758
– ident: e_1_2_6_18_1
  doi: 10.1093/eurheartj/ehaa177
– ident: e_1_2_6_2_1
  doi: 10.1016/j.jacc.2018.11.049
– ident: e_1_2_6_9_1
  doi: 10.1007/s11739‐012‐0862‐1
– ident: e_1_2_6_17_1
  doi: 10.1016/j.hrthm.2011.08.031
– ident: e_1_2_6_21_1
  doi: 10.1016/j.jacc.2007.01.024
– ident: e_1_2_6_32_1
  doi: 10.1016/j.amjmed.2015.11.035
– ident: e_1_2_6_45_1
  doi: 10.1002/ejhf.2468
– ident: e_1_2_6_14_1
  doi: 10.1161/CIRCULATIONAHA.105.584102
– ident: e_1_2_6_16_1
  doi: 10.1016/j.ijcard.2009.08.005
– ident: e_1_2_6_31_1
  doi: 10.1016/j.amjcard.2007.07.077
– ident: e_1_2_6_41_1
  doi: 10.1253/circrep.CR‐19‐0025
– ident: e_1_2_6_3_1
  doi: 10.1161/CIR.0b013e31829e8807
– ident: e_1_2_6_29_1
  doi: 10.1161/CIRCHEARTFAILURE.123.010599
– ident: e_1_2_6_34_1
  doi: 10.1093/eurheartj/ehi555
– ident: e_1_2_6_23_1
  doi: 10.1161/CIRCULATIONAHA.108.191095
– ident: e_1_2_6_27_1
  doi: 10.1016/j.jacc.2008.12.014
– ident: e_1_2_6_37_1
  doi: 10.1001/jama.299.22.2656
– ident: e_1_2_6_10_1
  doi: 10.1016/j.cardfail.2013.11.005
– ident: e_1_2_6_12_1
  doi: 10.1007/s00392‐017‐1162‐6
– ident: e_1_2_6_36_1
  doi: 10.1093/eurheartj/ehl259
– ident: e_1_2_6_38_1
  doi: 10.1056/NEJMoa1401426
– ident: e_1_2_6_11_1
  doi: 10.1016/j.ahj.2012.10.009
– ident: e_1_2_6_26_1
  doi: 10.1111/j.1542‐474X.1997.tb00325.x
– ident: e_1_2_6_19_1
  doi: 10.1056/NEJMoa1915928
– ident: e_1_2_6_40_1
  doi: 10.1016/s0735‐1097(00)01102‐5
– ident: e_1_2_6_43_1
  doi: 10.1093/europace/euw065
– ident: e_1_2_6_22_1
  doi: 10.1016/j.amjcard.2010.11.010
– ident: e_1_2_6_33_1
  doi: 10.1016/j.cardfail.2021.05.016
– ident: e_1_2_6_4_1
  doi: 10.1016/j.cjca.2017.08.022
– ident: e_1_2_6_30_1
  doi: 10.1093/eurheartj/ehz835
– ident: e_1_2_6_35_1
  doi: 10.1002/ejhf.2285
– ident: e_1_2_6_7_1
  doi: 10.1093/eurjhf/hfq002
– ident: e_1_2_6_42_1
  doi: 10.1111/j.1542‐474X.2009.00345.x
SSID ssj0017002
Score 2.4306529
Snippet Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.AIMSWhether...
SourceID proquest
crossref
SourceType Aggregation Database
Enrichment Source
Index Database
StartPage 1822
Title Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction ( VICTORIA ) trial
URI https://www.proquest.com/docview/2860405221
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKroS4IJ5ieWlAHBZVWVLXdVJu3dLSon1Iq3S1cInycLotkKI2PdA_zZ0T41eSSkVauESRZY0szWfPjD3zDSFvPB99Yj_B2IRR5jAv6TjdxGs7ScQ4AkRyjMt7yNMzPpqwT1edq0bjdy1raV3ER8lmZ13J_2gVx1Cvskr2HzRbCsUB_Ef94hc1jN8b6bjMZKtnXEm7pHxH0-EmURmniph6ljS_V3eCmp15sS5waUKnk2uSVVPxJpmMHZV6LrteF80smskcdnmHMM5XMqhfVdUpl2I57s-m6yhofjQcI4quGqXi2TRXOSNK6kjJGmpZeuhC0sei4zuYC924fLg0HczR_b0c94Pzi3FPXl-oFiN_fUswfvXWYqtDbRqpWsSl3gAj_Cm3xZdroU-8z2jHp7UkpZ_WUpRxx0Z8XeCaN7qgZWV5y821Ca0S8OxJ73tdSWqrbzPEjjFjHnRdtt0Gbu2wx9CM7rRCmtVWzK-zo7arC8C3mb7PzsPh5OQkDAZXwS2yTzHEwTN6v3f84XhYvoF5rs6YtYuyvFgufVeK3vamtp0J5SEF98hdE9pAT-P0PmmI_AG5fWqSNx6SX3W4goErWLjCLrhCHa6AcAULV5jlYOEKEkVQwhUUAsAg4D1YsIIEKyBYoQIraLCCAquUacGqZSqwggGrHjJgBQtWsGCFQwvVt6CA-ohMhoOgP3JMvxEnoZwWTrsjGE3jNOOdiMXotWFsIFjm-5lMucXQRrDYYxhiRK4sXoyFYKnPYtpFDaFl5O3HZC9f5OIJAZ52Whlv85i6KUs5j7PMF27Wle_QrSgSB-TQ6i1MDBm_7AnzLdQ04jSUKg6lig_I63LqD81As2vSK6v8EO2DfPSLcrFYr0Lqc7TTGGW1nt5gzjNyp9osz8lesVyLF-h1F_FLA88_WirnDA
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+baseline+electrocardiographic+measurements+and+outcomes+in+patients+with+high-risk+heart+failure%3A+Insights+from+the+VerICiguaT+Global+Study+in+Subjects+with+Heart+Failure+with+Reduced+Ejection+Fraction+%28VICTORIA%29+trial&rft.jtitle=European+journal+of+heart+failure&rft.au=Yogasundaram%2C+Haran&rft.au=Zheng%2C+Yinggan&rft.au=Ly%2C+Eric&rft.au=Ezekowitz%2C+Justin&rft.date=2023-10-01&rft.issn=1879-0844&rft.eissn=1879-0844&rft.volume=25&rft.issue=10&rft.spage=1822&rft_id=info:doi/10.1002%2Fejhf.3021&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1388-9842&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1388-9842&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1388-9842&client=summon